Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article
Special Issue

Herb-Derived Autophagy Enhancers in Neurodegenerative Diseases

View this Special Issue

Review Article | Open Access

Volume 2021 |Article ID 5538200 | https://doi.org/10.1155/2021/5538200

Sicong Li, Xu Sun, Lei Bi, Yujia Tong, Xin Liu, "Research Progress on Natural Product Ingredients’ Therapeutic Effects on Parkinson’s Disease by Regulating Autophagy", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 5538200, 11 pages, 2021. https://doi.org/10.1155/2021/5538200

Research Progress on Natural Product Ingredients’ Therapeutic Effects on Parkinson’s Disease by Regulating Autophagy

Academic Editor: Sachchida Nand Rai
Received10 Feb 2021
Revised17 Mar 2021
Accepted15 Apr 2021
Published24 Apr 2021

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disease in middle-aged and older adults. Abnormal proteins such as α-synuclein are essential factors in PD’s pathogenesis. Autophagy is the main participant in the clearance of abnormal proteins. The overactive or low function of autophagy leads to autophagy stress. Not only is it difficult to clear abnormal proteins but also it can cause damage to neurons. In this article, the effects of natural products ingredients, such as salidroside, paeoniflorin, curcumin, resveratrol, corynoxine, and baicalein, on regulating autophagy and protecting neurons were discussed in detail to provide a reference for the research and development of drugs for the treatment of PD.

1. Introduction

The prevalence of PD in the Chinese population over 65 years of age is 1.7% [1]. The main clinical features of PD are static tremor, bradykinesia, myotonia, and postural balance disorder. PD has two main pathological features: one is the degeneration and loss of dopaminergic neurons and other pigmented neurons in the substantia nigra compact area; and the other is eosinophilic inclusion bodies (Lewy bodies) in the cytoplasm of the remaining neurons. Overaccumulation of misfolded/aggregated proteins (e.g., mutant α-synuclein (A53T, A30P, and E46k)) or large accumulation of wild-type α-synuclein [2], as well as neurotoxins or mutant proteins (e.g., LRRK2 [3], DJ-1 [4], and PINK1 [5]), is responsible for the formation of Lewy bodies. Autophagy is an important mechanism for eukaryotic cells to clear damaged organelles, protein aggregates, and abnormal proteins using lysosomes. It can regulate the response to extracellular or intracellular pressure and signal, such as hypoxia, ischemia, growth factor deficiency, endoplasmic reticulum stress, and pathogen infection. Abnormal autophagy is a common cause of abnormal protein accumulation, such as α-synuclein and other proteins with aggregation tendency. Dopamine can react with α-synuclein in neurons and induce the posttranslational modification of α-synuclein. This process inhibits the fibrosis of α-synuclein protein and leads to the accumulation of α-synuclein protein in cells in the form of soluble toxicity, forming oligomer or oligoprotein, which eventually leads to injury or even death of neurons.

The etiology of PD is relatively complex, and there is still a lack of safe and efficient single treatment drugs, so we need to continue to strengthen the research on medicines to treat PD. Because of high efficiency and low toxicity, natural products have become the focus of current studies [69]. Natural products can eliminate misfolded α-synuclein by promoting autophagy. In this article, we reviewed the relevant researches on natural products, such as salidroside, astragaloside IV, paeoniflorin, curcumin, resveratrol, corynoxine, β-asarone, which eliminate the aggregation of abnormal protein by regulating autophagy to provide a reference for the development and researches of drugs for the treatment of PD.

2. Glycosides

2.1. Salidroside

Extracted from the dried roots and rhizomes of Rhodiola rosea L., salidroside has pharmacological effects of reducing pulmonary artery pressure [10], scavenging oxygen free radicals [11], promoting cell metabolism [12], and regulating cell autophagy [13]. mTOR is a receptor in the human body that regulates the autophagy signaling pathway and also plays an essential role in regulating cell growth, proliferation, and cell cycle. mTOR promotes neuronal survival, dendritic branching, and synaptic plasticity by phosphorylating the downstream substrate ribosomal 40S small subunit S6 protein kinase (70 kDa ribosomal protein S6 kinase, P70S6K). In vitro, salidroside pretreatment could activate α-synuclein clearance by promoting mTOR/p70S6K signaling pathway [10] and protect dopaminergic neurons from MPP+/MPTP damage by regulating NO pathway [13], ROS-NO-related mitochondrion pathway [14], and PI3K/AKT pathway [15]. Salidroside could reduce the necrosis and apoptosis of nerve cells by activating autophagy. Salidroside could make the LC3-II/LC3-I ratio rise and increase LC3-II and Bcl-2 expression and decrease Bax expression [16]. Pathologically, nearly 90% of the α-synuclein that made up the Lewy body was phosphorylated α-syn at Serine129 (p Ser129-α-syn). Salidroside could inhibit the increase of pSer129-α-syn level by improving the ubiquitin-proteasome system’s function, thus alleviating 6-OHDA-induced neuronal injury [17]. Related to the occult formation of autophagosomes, PINK1 (PTEN-induced putative kinase 1) and Parkin have been research hotspots in the field of Parkinson’s disease in recent years. Direct binding of PINK1 and Beclin 1 could promote the autophagosomal formation that was involved in mitochondrial dynamics, metabolism, and degradation of abnormal proteins [18]. PINK1 triggered mitochondrial autophagy by recruiting proteins, like Parkin, to the damaged mitochondrial surface [19]. In vivo, salidroside (50 mg/kg intragastrically administered for seven days) could significantly inhibit the expression of autophagy-pathway-related proteins in the nigra striatum of Parkinson’s model mice (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model). The expression of LC-3β and Beclin 1 in substantia nigra striatum could be inhibited, while the expression levels of PINK1 and Parkin and the number of TH positive neurons increased [20].

In addition to inhibiting autophagy, salidroside could also protect dopaminergic neurons through antiapoptosis, antioxidation effect and inhibiting the inflammatory response. Salidroside (50 mg/kg·d, 100 mg/kg·d, and 200 mg/kg·d intragastrically administrated for 12 weeks) could dose-dependently inhibit neuronal apoptosis, decrease MDA content, increase SOD activity, and inhibit p-JNK3/JNK3 and caspase-3 protein expression in the hippocampus of rats after traumatic brain injury. These results indicated that salidroside inhibited oxidative-stress-mediated apoptosis of rat hippocampal neurons by inhibiting the JNK3/caspase-3 signaling pathway [21]. Salidroside could activate the TGF-β1/Smad3 signaling pathway in ischemic stroke model mice, inhibit Bax expression, and promote the expression of Bcl-2, TGF-β1, and p-Smad3, thereby reducing the damage of nerve function and playing a protective role on nerve cells [22]. In terms of anti-inflammation, salidroside (50 μM) could not only indirectly reduce the production of NLRP3, pre-IL-1β, and pre-IL-18 by inhibiting the TLR4/MyD88/NF-κB signaling pathway but also directly inhibit neuronal pyroptosis by inhibiting the TXNIP/NLRP3/caspase-1 signaling pathway [23, 24].

2.2. Astragaloside IV (ASI)

Astragaloside IV, extracted from the dried roots of Astragalus propinquus Schischkin, has pharmacological effects of regulating autophagy [19], anti-inflammation [25], anti-ischemic [26], antifibrosis [27], antitumor [28], and immunomodulation effects [29]. Before injecting MPTP, intraperitoneally injecting astragaloside IV (100 mg/kg, Q12 h) could promote mitochondrial autophagy and reduce the accumulation of damaged mitochondria and mitochondrial reactive oxygen species. Thus, it inhibited mice astrocyte senescence and degenerative changes of dopaminergic neurons, which significantly increased the contents of striatal dopamine and homovanillic acid and improved the movement of the mouse dysfunction [30, 31].

Astrocytes were bridges connecting neurons and blood vessels involved in neural development, neurotransmitter transmission, brain metabolism, and blood flow regulation [32]. Astrocyte apoptosis was also involved in the pathogenesis of neurodegenerative diseases like Parkinson’s disease [33]. Astragaloside IV (6 mg/10 μl) could inhibit the apoptosis of primary astrocytes induced by MPP+ and upregulate p-JNK, Bax/Bcl-2 ratio, and caspase-3 activity [34]. Astragaloside (1, 2, 5, 10, 20, and 50 μg/ml) could promote the expression of tyrosine hydroxylase and dopamine transporter genes, Sonic hedgehog (Shh), Orphan nuclear hormone 1 (Nurr1), and Pituitary homeobox 3 (Ptx3) genes. Thus, it promoted the formation of neural stem cells into dopaminergic neurons [35].

Oxidative stress was one of the essential causes of mitochondrial dysfunction which participated in Parkinson’s disease. Astragaloside (50, 100, and 200 µmol/l) could dose-dependently regulate p38 mitogen-activated protein kinase (MAPK) signaling pathway, downregulate the ratio of Bax/Bcl-2 to inhibit the expression of α-synuclein, increase the expression of tyrosine hydroxylase (THh) in cells, and protect SH-SY5Y cells from oxidative stress injury caused by H2O2 [36]. Astragaloside (30 mg/ml) could promote the JAK2/STAT3 signaling pathway to suppress the dopamine-induced Parkinson’s model of SH-SY5Y cell apoptosis and oxidative stress injury [37]. Methionine sulfoxide reductase (Msr) had antioxidant effects and could repair proteins damaged by oxidative stress. Astragaloside (50 μM) could upregulate Msr function through the SIRT1-FOXO3a signaling pathway, thereby regulating mitochondrial function and having an antioxidant effect [38]. Endoplasmic reticulum stress played a driving role in the apoptosis of dopaminergic neurons. Oxidative stress, glucose deficiency, hypoxia, and calcium imbalance could lead to the accumulation of unfolded or misfolded proteins in cells, leading to ER stress. Involved in apoptosis, the C/EBP homologous protein was a landmark protein of endoplasmic reticulum stress [39]. CHOP could directly promote autophagy-related genes ATG 10, ATG5, p62, and ATG 7 by binding to the cis-acting element GTGCAACC region of autophagy-related gene promoter [40]. The expression of long noncoding RNA (lincRNA-p21) could promote the ubiquitination of C/EBP homologous protein (CHOP) and accelerate the degradation of the protein. Astragaloside IV could inhibit the expression of lincRNA-p21 in Parkinson’s disease model cells, thereby reducing the expression of CHOP protein and inhibiting the apoptosis of dopaminergic nerve cells [41]. Nucleotide binding and oligomerization domain-like (Nod) receptor family pyrin domain-containing 3 (NLRP3) inflammasome could promote the maturation and release of IL-1β, thus affecting the survival of dopaminergic neurons [42]. Inhibition of NLRP3 inflammasome activation could effectively improve neuroinflammation and dopaminergic neuron degeneration in PD. In terms of anti-inflammation, astragaloside IV significantly inhibited NF-κB-mediated activation of NLRP3 inflammasome and Nrf2 in vitro and in vivo [43].

2.3. Paeoniflorin

Paeoniflorin, extracted from the dried roots of Paeonia lactiflora Pall. and Paeonia suffruticosa Andr., has regulating autophagy [37], anti-inflammatory [44], analgesic [45], and antitumor [46] effect.

Paeoniflorin could promote the binding of autophagosome and lysosome, significantly downregulate intracellular ROS level, and inhibit the oxidative damage in SH-SY5Y cells caused by H2O2 [47]. Paeoniflorin (50 μmol/L) could upregulate the autophagy-lysosome and ubiquitin-proteasome pathways and promote the degradation of α-synuclein [48]. Paeoniflorin can also antagonize the damage of MPP+ and 6-OHDA on the autophagy-lysosome pathway [49, 50]. Sirtuins, especially SIRT1, were nicotinamide adenine dinucleotide dependent deacetylases that modulated the ubiquitin-proteasome pathway (UPP). UPP played an essential role in the normal function of neuronal synapses, synaptic protein turnover, plasticity, and long-term memory formation [51]. Paeoniflorin could improve cognitive impairment in mice with ischemia and hypoxia by activating SIRT1/NF-κB signaling pathway. Paeoniflorin (5 mg/kg intragastrically administrated daily for 9 days) could inhibit the neuronal damage caused by rotenone in mice, reduce the formation of Lewy bodies, and inhibit the expression of α-synuclein [52]. Pathological activation of acid-sensitive ion channels was one of the causes of dopaminergic neuron degeneration in Parkinson’s disease [53]. Paeoniflorin enhanced autophagy degradation of α-synuclein by blocking acid-sensitive ion channel 1A, thereby protecting dopamine neurons from 6-OHDA damage [54]. In terms of Alzheimer’s disease, paeoniflorin protected SH-SY5Y cells from attack of okadaic acid by interfering with cal protease/Akt/GSK-3β related pathways and inhibiting the stress response of microtubule structural system [55].

However, low bioavailability and difficulty in crossing the blood-brain barrier limited paeoniflorin’s therapeutic efficacy. In 2020, a kind of paeoniflorin polyamide nanocrystal and a new dosage form containing brain targeting ligand lactoferrin (Lf) and paeoniflorin (Pae) loaded in black phosphorus nanoplates were reported [56, 57]. These dosage forms could help paeoniflorin cross the blood-brain barrier and have good biocompatibility and biosafety.

3. Polyphenols

3.1. Curcumin

Curcumin, extracted from the dried roots of Curcuma longa L. and Curcuma rcenyujin Y., has pharmacological actions including anti-inflammatory [58], antioxidation [59], antitumor [60], antiapoptosis [61], and regulating autophagy [50] effects. In vitro, curcumin (40 umol/L) could increase the expression of autophagy-related protein lysosome membrane protein 2 (ALAMP2A), microtubule-associated protein 1 light chain 3 (LC3-II), and nuclear plasma protein determination of nuclear transcription factor EB (TBBB) in Parkinson’s disease model cells. Moreover, it could accelerate the transfer in the nuclei and the exercise of transcription TFEB function and promote autophagy-lysosome synthesis and autophagic clearance of α-syn [62, 63]. In vivo, intraperitoneally injecting curcumin could promote LC3-II protein expression in mice and inhibit the expression of P62, thus promoting autophagy. Intraperitoneally injecting curcumin could not only inhibit alpha Syn protein expression and DA neurons apoptosis in MPTP-induced Parkinson’s disease model mouse (curcumin 80 mg/kg for 14 days) and improve the mouse movement disorder [10] but also improve the adult mice memory retrieval disorder induced by sevoflurane (curcumin 300 mg/(kg·d), for six days) [64]. In addition, curcumin could also activate autophagy by downregulating PI3K/Akt/mTOR signaling pathway, inhibit the damage of hippocampal neurons, and improve the learning and memory ability of rats [65].

In addition to promoting autophagy, curcumin’s protective effect on nerve cells was also related to regulating MEK-ERK-CREB signaling pathways. In vitro 1 uM curcumin could significantly inhibit MPP+ induced JNK1, JNK2, upstream MKK4, and downstream c-Jun [66]. Curcumin could antagonize α-synuclein induced mitochondrial dynamic imbalance and corresponding functional damage by inhibiting the overactivation of ERK and the aggregation of mitochondrial mitotic protein DLP1 in mitochondria. At the concentration of 1 μmol/L, curcumin could not only inhibit the activation of NADPH oxidase in microglia cells [67] and promote the expression of SIRT3 to eliminate microglia-derived ROS [68] but also inhibit the apoptosis of dopaminergic neurons by activating the IGF-1/Akt/FoxO3a signaling pathway [69] and PI3K/AKT/Bcl-2 signaling pathway [70].

3.2. Resveratrol

Resveratrol, extracted from grape, peanut, Morus alba L., and Reynoutria japonica Houtt., has anti-inflammatory [71], antioxidation [72], regulating autophagy [67], anticonvulsant [73], anti-ischemic [74], and antitumor [75] effects. Resveratrol played a neuroprotective role by activating SIRT1, promoting mitochondrial autophagy, and improving mitochondrial dysfunction [76]. SIRT1 regulated mitochondrial function and inhibited oxidative stress by maintaining the deacetylation state of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), thus maintaining the constant level of PGC-1α. Resveratrol (20 mg/kg, intragastrically administered for 14 days) could protect dopaminergic neurons from the destruction of MPTP by activating the SIRT1/PGC-1α/autophagy pathway [77]. Moreover, it could improve the 6-OHDA-induced Parkinson’s disease in mice by activating phosphatidylinositol 3 kinase (PI3K)/protein kinase (Akt)/glycogen synthase kinase 3β (GSK-3β) signaling pathway [78]. AMP-activated protein kinase (AMPK) controlled the metabolic balance in vivo by regulating autophagy and protein degradation and maintained the balance of cell energy supply and demand by affecting multiple links of cell glucose and fat metabolisms. Resveratrol (100 mg/kg) could inhibit mitochondrial damage and apoptosis of dopaminergic neurons in the substantia nigra of PD model mice induced by MPTP [79] and rotenone [80] by activating the SIRT1/AMPK signaling pathway after 33 days of intragastric administration. Resveratrol (50 mg/kg, intragastrically administered for nine weeks) could inhibit autophagy in rats with chronic cerebral ischemia by activating the PI3K/Akt/mTOR signaling pathway [81]. In vitro, 60 μm/L resveratrol can upregulate the expression of PD-related genes PARKIN1, DJ-1, and PINK1 in zebrafish and inhibit the destruction of dopaminergic neurons induced by MPTP by regulating the Nrf2/ARE pathway [82]. As one of the antioxidative stress pathways in vivo, the NRF2/ARE pathway can regulate the REDOX level by regulating detoxification enzymes’ transcriptional level.

Poor water solubility, unstable chemical properties, and low bioavailability limited resveratrol’s efficacy. Resveratrol loaded in liposomes [83], polysorbate 80-coated poly(lactide) nanoparticles [83], and vitamin E loaded resveratrol nanoemulsion [84] exhibited better therapeutic effects than free resveratrol. In order to promote resveratrol to cross the blood-brain barrier, Li et al. [85] designed a series of pyridoxine-resveratrol hybrids as monoamine oxidase B inhibitors. Some of the compounds showed low cytotoxicity, good antioxidant activities, and high blood-brain barrier permeability.

4. Benzene

4.1. β-Asarone

Extracted from Acorus tatarinowii, β-asarone has anti-ischemic [86], antidepression [87], regulating autophagy [74], and antiepileptic [88] effects. Combination of β-asarone (15 mg/kg) and L-dopa (60 mg/kg) (intragastrically administrated twice a day for 30 days) could promote levodopa converted into the brain dopamine by increasing the permeability of the blood-brain barrier [89, 90]. Moreover, it could adjust the JNK/Bcl-2/Beclin 1 pathway and HSP70/MEF2D/Beclin 1 molecular chaperone-mediated autophagy pathway to reduce dopaminergic neurons injury induced by 6-OHDA in Parkinson’s model rats [91, 92]. β-Asarone could reduce the dose of levodopa by increasing the content of tyrosine hydroxylase and decreasing the content of dopamine decarboxylase in the brain tissues [93]. Endoplasmic reticulum autophagy also played an important role in the pathogenesis of Parkinson’s disease. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) was in dopaminergic neurons in the substantia nigra striatum of patients with Parkinson’s disease. β-asarone could regulate endoplasmic reticulum stress-autophagy by regulating the inositol-demanding enzyme 1/X-box binding protein 1 (IRE1/XBP1) pathway [94] and the PERK/CHOP/Bcl-2/Beclin 1 pathway [95]. In vivo and in vitro, β-asarone could inhibit the expression of long noncoding RNAs MALAT1 and α-synuclein to inhibit dopaminergic neuronal damage induced by MPP+ [96].

5. Alkaloids

5.1. Corynoxine

Corynoxine, extracted from Uncaria rhynchophylla (Miq.) Miq. ex Havil., has sedative [97], antiepileptic [98], and autophagy promoting [84] effects. Considered as a natural autophagy enhancer, corynoxine could induce autophagy in a concentration-dependent manner by regulating the Akt/mTOR pathway and promoting the clearance of wild-type and A53T-α-syn in SH-SY5Y cells and PC12 cells at concentrations of 6.25, 12.5, and 25 μM. This effect could be inhibited by 3-MA or enhanced by chloroquine [99].

Mammalian target of rapamycin (mTOR) could regulate age-related degenerative diseases and destroy transient proteins in cytoplasm and core organelles by regulating the autophagy-lysosomal pathway (ALP) [27]. Found to be an inhibitor of mTOR, corynoxine (15 μM) could effectively eliminate α-synuclein overexpression in N2A cells by inducing autophagy. This effect was related to the downregulation of the PI3K/Akt/mTOR signaling pathway and RPS6KB1/P70S6K (ribosomal protein S6 kinase, polypeptide (1)) and upregulation of MAP2K2/MEK2 (mitogen-activated protein kinase (2)) and PLK1 (polo-like kinase (1) functions) [100]. Intragastric administration of 10 mg/kg corynoxine for 12 weeks could improve movement disorders in rotenone-induced Parkinson’s disease mice. The effect was not significantly different from that of rapamycin (10 mg/kg) [101].

6. Flavonoids

6.1. Baicalein

Baicalein, extracted from Scutellaria baicalensis Georgi., has anti-inflammatory [102], antioxidation [103], antitumor [104], and antiepileptic [98] effects. The therapeutic effect of baicalein on Parkinson’s disease is related to inducing autophagy and regulating gene expression, antioxidation, and anti-inflammation effects.

Baicalein (5, 10, and 20 µmol/L) could dose-dependently promote the formation of autophagosomes in PC12 neurons, inhibit the activity of mTOR, and promote the clearance of α-syn. The effects above could be inhibited by 3-methyladenine [105]. Baicalein (100 mg/kg, intragastrically administrated for 6 weeks) improved rotenone-induced behavioral deficits, dopaminergic neuron loss, autophagy dysfunction, and mitochondrial dysfunction in mice [106]. Baicalein (280 mg/kg intragastrically administered for 7 days) could significantly improve Parkinson’s model mice’s abnormal behaviors induced by MPTP, which could shorten the total rod-climbing time, prolong the rotational latency, and increase the vertical movement [107].

In terms of regulating gene expression, the LIMK1 gene could not only participate in regulating synaptic remodeling and cytoskeleton stability of hippocampal neurons but also affect neuron migration by regulating Cofilin [108]. The SNCA gene was responsible for encoding the α -syn protein, whose mutation, duplication, or triplet could lead to autosomal dominant PD [109]. GLRA1 gene was closely related to anxiety disorder, schizophrenia, and hyperstartle response [110]. By analyzing the gene coexpression network, the baicalein regulation of LIM kinase 1 (LIMK1), SNCA, GLRA1, and other genes might play a core role in the gene coexpression network [111]. In terms of anti-inflammation, baicalein (30 mg/kg intragastrically administered for 7 days) could inhibit the aggregation of α-synuclein, activation of inflammatory bodies, and production of Cathepsin B after MPP + injected into the substantia nigra of rats, as well as the upregulating tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 in the substantia nigra and striatum of rats [112]. Neuroinflammation induced by inflammasomes was one of the pathogenic mechanisms of degeneration of dopaminergic neurons in the substantia nigra. Baicalein (100 mg/kg, 200 mg/kg, and 400 mg/kg, intragastrically administered for 4 weeks) could inhibit MPTP-induced mice nerve inflammation by inhibiting the NLRP3/caspase-1/GSDMD pathway [113].

In terms of antioxidation, baicalein could significantly reduce ROS and MDA levels in the brain and increase the activities of SOD and catalase (CAT). Injury of the ubiquitin-proteasome system was involved in the pathogenesis of Parkinson’s disease. Baicalein (10 mM) might attenuate proteasomal-inhibitor-induced apoptosis in PC12 cells by inhibiting mitochondrial pathways and caspase-8 and Bid-dependent pathways, which might be associated with its inhibition of reactive oxygen generation and glutathione depletion. 25 μM baicalein could protect dopaminergic neuroblastoma SH-SY5Y cells by inhibiting calcium homeostasis imbalance and mitochondrial damage caused by 6-OHDA+ ascorbic acid [114]. Moreover, baicalein could protect mitochondrial dysfunction by AMP-responsive element-binding protein (CREB) and glycogen synthase kinase-3β (GSK-3β) pathways [115].

7. Summary

Characterized by static tremor, bradykinesia, myotonia, and abnormal postural gait, Parkinson’s disease (PD) is a common degenerative disease of central nervous system in middle-aged and senile persons. Degeneration loss of dopaminergic neurons in substantia nigra (DA) and formation of eosinophilic inclusion body (Lewy body) can be widely found in PD patients. Autophagy can degrade α-syn and inhibit α-syn deposition in Lewy body. At present, the treatments of PD are mostly supplying dopamine in the brain, and there is no effective method to protect dopaminergic neurons, so it can only delay the progress of disease but cannot fundamentally treat PD.

Natural products are potential drug choices for the treatment of Parkinson’s disease due to their wide range of sources, multiple therapeutic targets, and easy access. Natural products can have various pharmacological actions that can have therapeutic effects on Parkinson’s disease, including antioxidation, anti-inflammation, and antiapoptosis [116, 117] effects.

As is summarized in Table 1, salidroside, resveratrol, and baicalein can promote the clearance of α-syn and protect dopaminergic neurons by regulating the JNK/Bcl-2/Beclin 1, HSP70/MEF2D/Beclin 1, and IRE1/XBP1 pathway and autophagy-related signaling pathways such as PERK/CHOP/Bcl-2/Beclin 1 and PI3K/Akt/mTOR. Abnormal aggregation of α-syn is the key pathological feature of Parkinson’s disease. The SNCA gene is responsible for encoding α-syn, and the abnormal expression of this gene will cause abnormal metabolism of neurons. Meanwhile, mutations of PD-related genes, such as PRKN, PINK1, and DJ-1, also affect the level of mitochondrial autophagy and normal physiological functions. Natural products like salidroside, resveratrol, and baicalein can regulate ALAMP2A, SNCA, PRKN, PINK1, and DJ-1 genes to protect autophagy inhibiting the apoptosis of dopaminergic neurons and promoting the elimination of α-syn. In addition to regulating autophagy, salidroside, astragaloside IV, paeoniflorin, resveratrol, and baicalein can also play an antioxidative and anti-inflammatory role in the treatment of Parkinson’s disease.


Chemical structurePharmacological actionSignal pathways

SalidrosideRegulating autophagy, antioxidation, anti-inflammation, and antiapoptosismTOR/p70S6K signaling pathway, JNK3/caspase-3 signaling pathway, ROS-NO-related mitochondrion pathway, and TGF-β1/Smad3 signaling pathway
TLR4/MyD88/NF-κB signaling pathway, TXNIP/NLRP3/caspase-1 signaling pathway, NO pathway, and PI3K/AKT pathway
Astragaloside IVRegulating autophagy, antioxidation, anti-inflammation, and antiapoptosisp38 MAPK signaling pathway, JNK3/caspase-3 signaling pathway JAK2/STAT3 signaling pathway, SIRT1-FOXO3a signaling pathway, and NF-κB/NLRP3 signaling pathway
PaeoniflorinRegulating autophagy, antioxidation, anti-inflammation, and antiapoptosisSIRT1/NF-κB signaling pathway, PI-3K/Akt/GSK-3β signaling pathway
CurcuminRegulating autophagy, antioxidation, anti-inflammation, and antiapoptosisPI3K/Akt/mTOR signaling pathway, MEK-ERK-CREB signaling pathway, and IGF-1/Akt/ FOXO3a signaling pathway
ResveratrolRegulating autophagy, antioxidation, anti-inflammation, and antiapoptosisSIRT1/PGC-1α signaling pathway, PI3K/Akt/GSK-3β signaling pathway, SIRT1/AMPK signaling pathway, PI3K/Akt/mTOR signaling pathway, and Nrf2/ARE signaling pathway
β-AsaroneRegulating autophagy and endoplasmic reticulum stress, as well as antiapoptosisJNK/Bcl-2/Beclin 1 pathway, IRE1/XBP1 pathway, and PERK/CHOP/Bcl-2/Beclin 1 pathway
CorynoxineRegulating autophagyAkt/mTOR pathway
BaicaleinRegulating autophagy and gene expression, antioxidation, and antiapoptosisNLRP3/caspase-1/GSDMD pathway, mitochondrial pathway, caspase-8 and Bid-dependent pathway, and CREB and glycogen synthase kinase-3β (GSK-3β) pathway

At present, natural products are mostly used in the form of the compound for the treatment of Parkinson’s disease and rarely used in the form of monomer. Compared with the compound decoction, the monomer component has the advantages of easy access and definite pharmacodynamic components, making it easier to be popularized and applied in clinical practice. Currently, studies on the efficacy of natural products are still in the stage of animal trials, and relevant researchers should continue to finish clinical trials on this basis to promote the continuous development of Parkinson’s disease drugs.

Data Availability

The data used to support the findings of this study are included within the article.

Disclosure

The funders had no role in manuscript writing, editing, approval, or decision to publish.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Sicong Li and Xu Sun were responsible for the initial outline, draft writing, revisions for intellectual content, and final approval; Lei Bi and Yujia Tong were responsible for data interpretation, presentation, draft writing, and revisions for intellectual content; Xin Liu is the corresponding author and was responsible for draft writing and final approval.

Acknowledgments

The authors thank all the scholars who deeply love and popularize the basic knowledge and expand natural products’ influence.

References

  1. T. B. Sherer, “Guidelines for the treatment of Parkinson’s disease in China (fourth edition),” Chinese Journal of Neurology, vol. 53, no. 12, pp. 973–986, 2020. View at: Google Scholar
  2. T. B. Sherer, R. Betarbet, C. M. Testa et al., “Mechanism of toxicity in rotenone models of Parkinson’s disease,” The Journal of Neuroscience, vol. 23, no. 34, pp. 10756–10764, 2003. View at: Publisher Site | Google Scholar
  3. A. B. West, D. J. Moore, S. Biskup et al., “From the Cover: Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity,” Proceedings of the National Academy of Sciences, vol. 102, no. 46, pp. 16842–16847, 2005. View at: Publisher Site | Google Scholar
  4. V. Bonifati, P. Rizzu, M. J. van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” Science, vol. 299, no. 5604, pp. 256–259, 2003. View at: Publisher Site | Google Scholar
  5. I. Kamienieva, J. Duszyński, and J. Szczepanowska, “Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease,” Translational Neurodegeneration, vol. 10, no. 1, p. 5, 2021. View at: Publisher Site | Google Scholar
  6. S. N. Rai, H. Birla, W. Zahra, S. S. Singh, and S. P. Singh, “Immunomodulation of Parkinson’s disease using Mucuna pruriens (Mp),” Journal of Chemical Neuroanatomy, vol. 85, pp. 27–35, 2017. View at: Publisher Site | Google Scholar
  7. S. K. Yadav, S. N. Rai, and S. P. Singh, “Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model,” Journal of Chemical Neuroanatomy, vol. 80, pp. 1–10, 2017. View at: Publisher Site | Google Scholar
  8. S. N. Rai, H. Birla, S. S. Singh et al., “Mucuna pruriens protects against MPTP intoxicated neuroinflammation in Parkinson’s disease through NF-κB/pAKT signaling pathways,” Frontiers in Aging Neuroscience, vol. 9, p. 421, 2017. View at: Publisher Site | Google Scholar
  9. S. N. Rai, W. Zahra, S. S. Singh et al., “Anti-inflammatory activity of ursolic acid in MPTP-induced parkinsonian mouse model,” Neurotoxicity Research, vol. 36, no. 3, pp. 452–462, 2019. View at: Publisher Site | Google Scholar
  10. M. Chen, H. Cai, C. Yu et al., “Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways,” Neurotoxicity Research, vol. 8, no. 1, pp. 12–27, 2016. View at: Google Scholar
  11. F. Fan, L. Yang, R. Li et al., “Salidroside as a potential neuroprotective agent for ischemic stroke: a review of sources, pharmacokinetics, mechanism and safety,” Biomedicine & Pharmacotherapy, vol. 129, p. 110458, 2020. View at: Publisher Site | Google Scholar
  12. T. Song, P. Wang, C. Li et al., “Salidroside simultaneously reduces de novo lipogenesis and cholesterol biosynthesis to attenuate atherosclerosis in mice,” Biomedicine & Pharmacotherapy, vol. 134, p. 111137, 2021. View at: Publisher Site | Google Scholar
  13. X. Li, X. Ye, X. Li et al., “Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway,” Brain Research, vol. 1382, pp. 9–18, 2011. View at: Publisher Site | Google Scholar
  14. S. Wang, H. He, L. Chen, W. Zhang, X. Zhang, and J. Chen, “Protective effects of salidroside in the MPTP/MPP+-Induced model of Parkinson’s disease through ROS-NO-related mitochondrion pathway,” Molecular Neurobiology, vol. 51, no. 2, pp. 718–728, 2015. View at: Publisher Site | Google Scholar
  15. L. Zhang, W. Ding, H. Sun et al., “Salidroside protects PC12 cells from MPP+-induced apoptosis via activation of the PI3K/Akt pathway,” Food and Chemical Toxicology, vol. 50, no. 8, pp. 2591–2597, 2012. View at: Publisher Site | Google Scholar
  16. S. K. J. Magani, S. D. Mupparthi, B. P. Gollapalli et al., “Salidroside - can it be a multifunctional drug?” Current Drug Metabolism, vol. 21, no. 7, pp. 512–524, 2020. View at: Publisher Site | Google Scholar
  17. T. Li, Study on the Effect and Mechanism of Salidroside on Pathologic α-synuclein, Fourth Military Medical University, London, UK, 2017.
  18. J. Lin, K. Chen, W. Chen et al., “Paradoxical mitophagy regulation by PINK1 and TUFm,” Molecular Cell, vol. 80, no. 4, pp. 607–620, 2020. View at: Publisher Site | Google Scholar
  19. P. M. J. Quinn, P. I. Moreira, A. F. Ambrósio et al., “PINK1/PARKIN signalling in neurodegeneration and neuroinflammation,” Shaanxi Medical Journal, vol. 8, no. 1, p. 189, 2020. View at: Publisher Site | Google Scholar
  20. S. H. Wang, P. Xu, C. Kang et al., “Experimental study on the effect of salidroside on autophagy pathway in MPTP Parkinson’s disease mouse model,” Shaanxi Medical Journal, vol. 49, no. 10, pp. 1215–1218, 2020. View at: Google Scholar
  21. Y. P. Wang, B. C. Zhang, C. M. Wen et al., “Effects of salidroside on hippocampal neuron injury and JNK3/caspase-3 signaling pathway in rats with brain injury,” Chinese Journal of Practical Neurological Diseases, vol. 23, no. 21, pp. 1841–1846, 2020. View at: Google Scholar
  22. J. Cai, W. J. Huang, S. X. Liu et al., “To investigate the neuroprotective effect of salidroside on ischemic stroke in rats based on TGF-β1/Smad3 signal,” Chinese Herbal Medicine, vol. 51, no. 24, pp. 6294–6301, 2020. View at: Google Scholar
  23. F. Zhou, J. Ju, Y. Fang et al., “Salidroside protected against MPP +‐induced Parkinson’s disease in PC12 cells by inhibiting inflammation, oxidative stress and cell apoptosis,” Biotechnology and Applied Biochemistry, vol. 66, no. 2, pp. 247–253, 2019. View at: Publisher Site | Google Scholar
  24. X. Zhang, Y. Zhang, R. Li, L. Zhu, B. Fu, and T. Yan, “Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis,” Aging, vol. 12, no. 10, pp. 9405–9426, 2020. View at: Publisher Site | Google Scholar
  25. Y. Ying, C.-B. Sun, S.-Q. Zhang et al., “Induction of autophagy via the TLR4/NF-κB signaling pathway by astragaloside IV contributes to the amelioration of inflammation in RAW264.7 cells,” Biomedicine & Pharmacotherapy, vol. 137, p. 111271, 2021. View at: Publisher Site | Google Scholar
  26. S. J. Du, Y. Zhang, Y. M. Zhao et al., “Astragaloside IV attenuates cerebral ischemia‑reperfusion injury in rats through the inhibition of calcium‑sensing receptor‑mediated apoptosis,” International Journal of Molecular Medicine, vol. 47, no. 1, pp. 302–314, 2021. View at: Publisher Site | Google Scholar
  27. P. Gao, X. Du, L. Liu et al., “Astragaloside IV alleviates tacrolimus-induced chronic nephrotoxicity via p62-keap1-nrf2 pathway,” Frontiers in Pharmacology, vol. 11, p. 610102, 2021. View at: Publisher Site | Google Scholar
  28. Y. eng, W. Wang, M. Chen et al., “GBP1 facilitates indoleamine 2,3-dioxygenase extracellular secretion to promote the malignant progression of lung cancer,” Frontiers in Pharmacology, vol. 11, p. 622467, 2021. View at: Publisher Site | Google Scholar
  29. N. Yakubogullari, F. O. Coven, N. Cebi et al., “Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine,” Biologicals, vol. 11, no. 21, pp. S1045–S1056, 2021. View at: Publisher Site | Google Scholar
  30. M. L. Xia, X. H. Xie, J. H. Ding et al., “Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease,” Journal of Neuroinflammation, vol. 17, no. 1, p. 105, 2020. View at: Publisher Site | Google Scholar
  31. L. X. Xie, H. L. Liu, Z. H. Xia et al., “The neuroprotective effect of astragaloside IV on Parkinson’s disease in vitro and in vivo,” Chinese Pharmacy, vol. 21, no. 23, pp. 2132–2134, 2010. View at: Google Scholar
  32. G. Seifert, K. Schilling, and C. Steinhäuser, “Astrocyte dysfunction in neurological disorders: a molecular perspective,” Nature Reviews Neuroscience, vol. 7, no. 3, pp. 194–206, 2006. View at: Publisher Site | Google Scholar
  33. K. Szydlowska, M. Zawadzka, and B. Kaminska, “Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo,” Journal of Neurochemistry, vol. 99, no. 3, pp. 965–975, 2006. View at: Publisher Site | Google Scholar
  34. L. Xia, D. Guo, and B. Chen, “Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes,” Experimental and Therapeutic Medicine, vol. 14, no. 6, pp. 5569–5575, 2017. View at: Publisher Site | Google Scholar
  35. H. Gao, L. Dou, L. Shan, Y. Sun, and W. Li, “Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali,” Neuroreport, vol. 29, no. 7, pp. 577–582, 2018. View at: Publisher Site | Google Scholar
  36. X. Liu, J. Zhang, S. Wang, J. Qiu, and C. Yu, “Astragaloside IV attenuates the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway,” International Journal of Molecular Medicine, vol. 40, no. 6, pp. 1772–1780, 2017. View at: Publisher Site | Google Scholar
  37. Z. H. Xu, H. Huang, D. F. Yang et al., “Astragalus armour glycosides IV suppress the Parkinson’s disease induced by dopamine SH SY5Y cells apoptosis related mechanism,” Chinese Journal of Geriatric Cardiocerebrovascular Disease, vol. 22, no. 12, pp. 1312–1315, 2020. View at: Google Scholar
  38. Y. Liu, L. Chong, X. Li et al., “Astragaloside IV rescues MPP+-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A,” Experimental and Therapeutic Medicine, vol. 14, no. 3, pp. 2650–2656, 2017. View at: Publisher Site | Google Scholar
  39. D. Ron and J. F. Habener, “CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription,” Genes Deviation, vol. 6, no. 3, pp. 439–453, 2002. View at: Google Scholar
  40. W. B’ chir, A. C. Maurin, V. Carraro et al., “The eIF2α/ATF4 pathway is essential for stress⁃induced autophagy gene expression,” Genes Deviation, vol. 6, 2002. View at: Google Scholar
  41. B. Ge, S.-L. Li, and F.-R. Li, “Astragaloside-IV regulates endoplasmic reticulum stress-mediated neuronal apoptosis in a murine model of Parkinson’s disease via the lincRNA-p21/CHOP pathway,” Experimental and Molecular Pathology, vol. 115, p. 104478, 2020. View at: Publisher Site | Google Scholar
  42. F. Yin, H. Sancheti, I. Patil, and E. Cadenas, “Energy metabolism and inflammation in brain aging and Alzheimer’s disease,” Free Radical Biology and Medicine, vol. 100, pp. 108–122, 2016. View at: Publisher Site | Google Scholar
  43. C. Yang, Y. Mo, E. Xu et al., “Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson’s disease mouse model,” International Immunopharmacology, vol. 75, p. 105651, 2019. View at: Publisher Site | Google Scholar
  44. M.-X. Yu, X.-Q. Ma, X. Song et al., “Validation of the key active ingredients and anti-inflammatory and analgesic effects of shenjin huoxue mixture against osteoarthritis by integrating network pharmacology approach and thin-layer chromatography analysis,” Drug Design, Development and Therapy, vol. 14, pp. 1145–1156, 2020. View at: Publisher Site | Google Scholar
  45. C. Jiang, L. Xu, L. Chen et al., “Selective suppression of microglial activation by paeoniflorin attenuates morphine tolerance,” European Journal of Pain, vol. 19, no. 7, pp. 908–919, 2015. View at: Publisher Site | Google Scholar
  46. K. Niu, Y. Liu, Z. Zhou, X. Wu, H. Wang, and J. Yan, “Antitumor effects of paeoniflorin on hippo signaling pathway in gastric cancer cells,” Journal of Oncology, vol. 2021, pp. 1–12, 2021. View at: Publisher Site | Google Scholar
  47. J. P. Yu, Z. Y. Song, F. Z. Li et al., “Paeoniflorin inhibits H2O2-induced oxidative damage in SH-SY5Y cells by promoting autophagy,” Journal of Hunan University of Chinese Medicine, vol. 40, no. 6, pp. 653–659, 2020. View at: Google Scholar
  48. Z. Cai, X. Zhang, Y. Zhang et al., “The impact of paeoniflorin on α-synuclein degradation pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, p. 182495, 2015. View at: Google Scholar
  49. X. S. Gu, F. Wang, L. F. Hu et al., “Protective effect of paeoniflorin on 6-hydroxydopamine-induced PC12 cell injury,” Journal of Clinical Neurology, vol. 31, no. 4, pp. 283–287, 2018. View at: Google Scholar
  50. Y. M. Zhang, Paeoniflorin Protects PC12 Cells through Autophagy-Lysosomal pathway, Suzhou University, London, UK, 2011.
  51. S. C. Johnson, P. S. Rabinovitch, and M. Kaeberlein, “mTOR is a key modulator of ageing and age-related disease,” Nature, vol. 493, no. 7432, pp. 338–345, 2013. View at: Publisher Site | Google Scholar
  52. Y. X. Liu, F. X. Tu, and Z. B. Lin, “Effects of paeoniflorin on cognitive function of neonatal rats with hypoxic-ischemic brain injury,” Chinese Journal of Clinical Pharmacology, vol. 36, no. 24, pp. 3992–3994, 2020. View at: Google Scholar
  53. B. L. Hu and C. Y. Guo, “Progress in neuroprotective mechanism of paeoniflorin,” Journal of Neuropharmacology, vol. 5, no. 6, pp. 51–56, 2015. View at: Google Scholar
  54. X.-S. Gu, F. Wang, C.-Y. Zhang et al., “Neuroprotective effects of paeoniflorin on 6-OHDA-lesioned rat model of Parkinson’s disease,” Neurochemical Research, vol. 41, no. 11, pp. 2923–2936, 2016. View at: Publisher Site | Google Scholar
  55. X.-H. Ma, W.-J. Duan, Y.-S. Mo et al., “Neuroprotective effect of paeoniflorin on okadaic acid-induced tau hyperphosphorylation via calpain/Akt/GSK-3β pathway in SH-SY5Y cells,” Brain Research, vol. 1690, pp. 1–11, 2018. View at: Publisher Site | Google Scholar
  56. C. Wu, B. Li, Y. Zhang et al., “Intranasal delivery of paeoniflorin nanocrystals for brain targeting,” Asian Journal of Pharmaceutical Sciences, vol. 15, no. 3, pp. 326–335, 2020. View at: Publisher Site | Google Scholar
  57. S. Xiong, Z. Li, Y. Liu et al., “Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson’s disease,” Biomaterials, vol. 260, p. 120339, 2020. View at: Publisher Site | Google Scholar
  58. M. Filippelli, G. Campagna, P. Vito et al., “Anti-inflammatory effect of curcumin, homotaurine, and vitamin D3 on human vitreous in patients with diabetic retinopathy,” Frontiers in Neurology, vol. 11, p. 592274, 2021. View at: Publisher Site | Google Scholar
  59. F. Wu, H. Zhao, J. Shi et al., “Preparation and evaluation of an injectable curcumin loaded chitosan/hydroxyapatite cement,” Journal of Biomaterials Applications, vol. 23, 2021. View at: Publisher Site | Google Scholar
  60. L. Xu, X. Wang, X. Y. Wang et al., “Curcumin mediates IL-6/STAT3 signaling pathway to repair intestinal mucosal injury induced by 5-FU chemotherapy for colon cancer,” Zhongguo Zhong Yao Za Zhi, vol. 46, no. 3, pp. 670–677, 2021. View at: Publisher Site | Google Scholar
  61. H. Zhou, Y. Ning, G. Zeng, C. Zhou, and X. Ding, “Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT,” Oncology Reports, vol. 45, no. 4, p. 11, 2021. View at: Publisher Site | Google Scholar
  62. L. L. Gao, C. H. Wu, and W. W. Cai, “Effects of salidroside on neurological function after cerebral hemorrhage in rats,” China Journal of Health Standard Management, vol. 10, no. 2, pp. 118–121, 209. View at: Google Scholar
  63. F. Wu, B. Xu, S. L. Liang et al., “Curcumin protects dopaminergic neurons in Parkinson’s disease by activating autophagy,” Chinese Journal of Neurology, vol. 17, no. 10, pp. 973–980, 2018. View at: Google Scholar
  64. J. Huang, J. Yong, D. T. Wang et al., “Curcumin inhibits sevoflurane-induced memory impairment in mice by activating autophagy in hippocampal neurons,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 39, no. 7, pp. 838–841, 2019. View at: Google Scholar
  65. C. Wang, X. Zhang, Z. Teng, T. Zhang, and Y. Li, “Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice,” European Journal of Pharmacology, vol. 740, pp. 312–320, 2014. View at: Publisher Site | Google Scholar
  66. S. Yu, Y. L. Liu, Y. Wang et al., “The protective mechanism of curcumin on MPP∼+ induced Parkinson’s disease in vitro model,” Advances in Anatomical Science, vol. 19, no. 3, pp. 272–274, 2013. View at: Google Scholar
  67. Q. L. Cui, “Study on the mechanism of curcumin inhibiting NADPH oxidase in microglia to protect dopaminergic cells,” Chinese Journal of Practical Neurological Diseases, vol. 18, no. 11, pp. 37–39, 2015. View at: Google Scholar
  68. B. C. Cheng, H. Y. Bai, S. R. Zheng et al., “Protective effect of curcumin on rotenone-induced dopaminergic neuron damage in substantia nigra,” Chinese General Practice, vol. 19, no. 12, pp. 1462–1466, 2016. View at: Google Scholar
  69. MeN. Li, Z. K. Ma, and H. Y. Bai, “Curcumin protects the PD model induced by rotenone in PC12 cells through IGF-1/Akt/FoxO3a pathway,” Journal of Stroke and Neurological Disorders, vol. 34, no. 7, pp. 588–592, 2017. View at: Google Scholar
  70. F. S. Tabatabaei Mirakabad, M. S. Khoramgah, F. Tahmasebinia et al., “The effect of low-level laser therapy and curcumin on the expression of LC3, ATG10 and BAX/BCL2 ratio in PC12 cells induced by 6-hydroxide dopamine,” Journal of Lasers in Medical Sciences, vol. 11, no. 3, pp. 299–304, 2020. View at: Publisher Site | Google Scholar
  71. M. Asgharpour and A. Alirezaei, “Herbal antioxidants in dialysis patients: a review of potential mechanisms and medical implications,” Renal Failure, vol. 43, no. 1, pp. 351–361, 2021. View at: Publisher Site | Google Scholar
  72. Ó. A. Muñoz-Bernal, A. J. Coria-Oliveros, L. A. de la Rosa et al., “Cardioprotective effect of red wine and grape pomace,” Food Research International, vol. 140, p. 110069, 2021. View at: Publisher Site | Google Scholar
  73. H.-J. Kim, I.-K. Kim, W. Song, J. Lee, and S. Park, “The synergic effect of regular exercise and resveratrol on kainate-induced oxidative stress and seizure activity in mice,” Neurochemical Research, vol. 38, no. 1, pp. 117–122, 2013. View at: Publisher Site | Google Scholar
  74. L. Subedi and B. P. Gaire, “Phytochemicals as regulators of microglia/macrophages activation in cerebral ischemia,” Pharmacological Research, vol. 165, p. 105419, 2021. View at: Publisher Site | Google Scholar
  75. M. Yang, Z. Li, J. Tao et al., “Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells,” Journal of Cancer Research and Clinical Oncology, vol. 147, no. 4, pp. 1101–1113, 2021. View at: Publisher Site | Google Scholar
  76. J. Long, H. Gao, L. Sun, J. Liu, and X. Zhao-Wilson, “Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model,” Rejuvenation Research, vol. 12, no. 5, pp. 321–331, 2009. View at: Publisher Site | Google Scholar
  77. X. O. Yang, G. W. Yang, Z. X. Liu et al., “Effect of resveratrol on neurodegenerative disease in 6-OHDA-induced Parkinson’s disease mice through PI3K/Akt/GSK-3β pathway,” Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, vol. 18, no. 12, pp. 1880–1883, 2020. View at: Google Scholar
  78. G. Mudò, J. Mäkelä, V. D. Liberto et al., “Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease,” Cellular and Molecular Life Sciences, vol. 69, no. 7, pp. 1153–1165, 2012. View at: Publisher Site | Google Scholar
  79. Y. J. Guo, S. Y. Dong, W. J. Zhao et al., “Resveratrol alleviates MPTP-induced dopaminergic neuron loss in mice through the SIRT1/AMPK signaling pathway,” International Journal of Neurology and Neurosurgery, vol. 43, no. 2, pp. 97–102, 2016. View at: Google Scholar
  80. Y. Wu, X. Li, J. X. Zhu et al., “Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease,” Neurosignals, vol. 19, no. 3, pp. 163–174, 2011. View at: Publisher Site | Google Scholar
  81. N. Wang, Study on the Mechanism of Resveratrol Inhibiting Autophagy to Improve Chronic Cerebral Ischemic Cognitive dysfunction, Jilin University, London, UK, 2020.
  82. J. L. Peng, Y. M. Wu, H. R. Hong et al., “Study on the effect of resveratrol on the toxicity of MPTP by Nrf2/ARE pathway,” Journal of Chengdu Medical College, vol. 12, no. 1, pp. 7–12, 2017. View at: Google Scholar
  83. Y. Wang, H. Xu, Q. Fu, R. Ma, and J. Xiang, “Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats,” Journal of the Neurological Sciences, vol. 304, no. 1-2, pp. 29–34, 2011. View at: Publisher Site | Google Scholar
  84. R. Pangeni, S. Sharma, G. Mustafa, J. Ali, and S. Baboota, “Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress,” Nanotechnology, vol. 25, no. 48, p. 485102, 2014. View at: Publisher Site | Google Scholar
  85. W. Li, X. Yang, Q. Song et al., “Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease,” Bioorganic Chemistry, vol. 97, p. 103707, 2020. View at: Publisher Site | Google Scholar
  86. B. Xiao, X. Huang, Q. Wang, and Y. Wu, “Beta-asarone alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and NLRP3 inflammasome mediated pyroptosis,” Biological and Pharmaceutical Bulletin, vol. 43, no. 7, pp. 1046–1051, 2020. View at: Publisher Site | Google Scholar
  87. Y. Zhang, Y. Long, S. Yu et al., “Natural volatile oils derived from herbal medicines: a promising therapy way for treating depressive disorder,” Pharmacological Research, vol. 164, p. 105376, 2021. View at: Publisher Site | Google Scholar
  88. F. Liu, Q. Zhao, S. Liu et al., “Revealing the pharmacological mechanism of Acorus tatarinowii in the treatment of ischemic stroke based on network pharmacology,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, 2020. View at: Publisher Site | Google Scholar
  89. L. P. Huang, B. L. Ning, N. B. Wang et al., “Effects of β-asaryl ether combined with levodopa on molecular chaperon-mediated autophagy in 6-OHDA-induced Parkinson’s model rats [J/OL],” Traditional Chinese Medicine, vol. 7, pp. 1720–1724, 2020. View at: Google Scholar
  90. L. Huang, M. Deng, S. Zhang, Y. Fang, and L. Li, “Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar,” Clinical and Experimental Pharmacology & Physiology, vol. 41, no. 9, pp. 685–690, 2014. View at: Publisher Site | Google Scholar
  91. L.-P. Huang, M.-Z. Deng, Y.-P. He, and Y.-Q. Fang, “β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62,” Clinical and Experimental Pharmacology and Physiology, vol. 42, no. 3, pp. 269–277, 2015. View at: Publisher Site | Google Scholar
  92. S. Zhang, X.-H. Gui, L.-P. Huang et al., “Neuroprotective effects of β-asarone against 6-hydroxy dopamine-induced parkinsonism via JNK/Bcl-2/Beclin-1 pathway,” Molecular Neurobiology, vol. 53, no. 1, pp. 83–94, 2016. View at: Publisher Site | Google Scholar
  93. B. L. Ning, Q. X. Zhang, M. Z. Deng et al., “β-asarone reduces the dose of metobar in PD model rats,” Journal of Guangzhou University of Chinese Medicine, vol. 36, no. 6, pp. 889–896, 2019. View at: Google Scholar
  94. B. Ning, M. Deng, Q. Zhang, N. Wang, and Y. Fang, “β-Asarone inhibits IRE1/XBP1 endoplasmic reticulum stress pathway in 6-OHDA-induced parkinsonian rats,” Neurochemical Research, vol. 41, no. 8, pp. 2097–2101, 2016. View at: Publisher Site | Google Scholar
  95. B. Ning, Q. Zhang, N. Wang, M. Deng, and Y. Fang, “β-Asarone regulates ER stress and autophagy via inhibition of the PERK/CHOP/Bcl-2/Beclin-1 pathway in 6-OHDA-induced parkinsonian rats,” Neurochemical Research, vol. 44, no. 5, pp. 1159–1166, 2019. View at: Publisher Site | Google Scholar
  96. Q.-S. Zhang, Z.-H. Wang, J.-L. Zhang, Y.-L. Duan, G.-F. Li, and D.-L. Zheng, “Beta-asarone protects against MPTP-induced Parkinson’s disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression,” Biomedicine & Pharmacotherapy, vol. 83, pp. 153–159, 2016. View at: Publisher Site | Google Scholar
  97. R. S. M. de Carvalho, F. S. Duarte, and T. C. M. de Lima, “Involvement of GABAergic non-benzodiazepine sites in the anxiolytic-like and sedative effects of the flavonoid baicalein in mice,” Behavioural Brain Research, vol. 221, no. 1, pp. 75–82, 2011. View at: Publisher Site | Google Scholar
  98. P. Fu, Q. Yuan, Y. Sun et al., “Baicalein ameliorates epilepsy symptoms in a pilocarpine-induced rat model by regulation of IGF1R,” Neurochemical Research, vol. 45, no. 12, pp. 3021–3033, 2020. View at: Publisher Site | Google Scholar
  99. L.-L. Chen, J.-X. Song, J.-H. Lu et al., “Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway,” Journal of Neuroimmune Pharmacology, vol. 9, no. 3, pp. 380–387, 2014. View at: Publisher Site | Google Scholar
  100. L.-L. Chen, Y.-B. Wang, J.-X. Song et al., “Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy,” Autophagy, vol. 13, no. 11, pp. 1969–1980, 2017. View at: Publisher Site | Google Scholar
  101. Y. J. Huang, C. Li, L. L. Chen et al., “Effects of conoxin on motor function of rotenone-induced Parkinson’s disease mice,” Journal of Qingdao University (Medical Sciences), vol. 56, no. 2, pp. 153–155, 2020. View at: Google Scholar
  102. Y. Li, D. Yang, Y. Jia et al., “Research Note: anti-inflammatory effects and antiviral activities of baicalein and chlorogenic acid against infectious bursal disease virus in embryonic eggs,” Poultry Science, vol. 100, no. 4, p. 100987, 2021. View at: Publisher Site | Google Scholar
  103. Q. Y. Bai, S. M. Tao, J. H. Tian et al., “Progress of research on effect and mechanism of Scutellariae Radix on preventing liver diseases,” Zhongguo Zhong Yao Za Zhi, vol. 45, no. 12, pp. 2808–2816, 2020. View at: Publisher Site | Google Scholar
  104. D. Qiao, J. Jin, J. Xing et al., “Baicalein inhibits gastric cancer cell proliferation and migration through a FAK interaction via AKT/mTOR signaling,” The American Journal of Chinese Medicine, vol. 49, no. 2, pp. 525–541, 2021. View at: Publisher Site | Google Scholar
  105. L. X. Xie, F. Y. Zhao, M. Wang et al., “Baicalin promotes the clearance of alpha-synuclein overexpressed in nerve cells by inhibiting the mTOR pathway and activating autophagy,” Journal of Hebei Medical University, vol. 38, no. 5, pp. 585–589, 2017. View at: Google Scholar
  106. Q. Hu, V. N. Uversky, M. Huang et al., “Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson’s disease,” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1862, no. 10, pp. 1883–1890, 2016. View at: Publisher Site | Google Scholar
  107. X. Mu, G.-R. He, X. Yuan, X.-X. Li, and G.-H. Du, “Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice,” Pharmacology Biochemistry and Behavior, vol. 98, no. 2, pp. 286–291, 2011. View at: Publisher Site | Google Scholar
  108. Y.-F. Chen, S.-N. Wu, J.-M. Gao et al., “The antioxidant, anti-inflammatory, and neuroprotective properties of the synthetic chalcone derivative AN07,” Molecules, vol. 25, no. 12, p. 2907, 2020. View at: Publisher Site | Google Scholar
  109. M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the -synuclein gene identified in families with Parkinson’s disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997. View at: Publisher Site | Google Scholar
  110. N. Schaefer, J. Signoret-Genest, C. R. von Collenberg et al., “Anxiety and startle phenotypes in glrb spastic and Glra1 spasmodic mouse mutants,” Frontiers in Molecular Neuroscience, vol. 13, p. 152, 2020. View at: Publisher Site | Google Scholar
  111. L. Gao, C. Li, R.-Y. Yang et al., “Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson’s disease: a microarray study,” Pharmacology Biochemistry and Behavior, vol. 133, pp. 155–163, 2015. View at: Publisher Site | Google Scholar
  112. L. Kuang, X. Cao, and Z. Lu, “Baicalein protects against rotenone-induced neurotoxicity through induction of autophagy,” Biological & Pharmaceutical Bulletin, vol. 40, no. 9, pp. 1537–1543, 2017. View at: Publisher Site | Google Scholar
  113. W. Rui, S. Li, H. Xiao, M. Xiao, and J. Shi, “Baicalein attenuates neuroinflammation by inhibiting NLRP3/caspase-1/GSDMD pathway in MPTP-induced mice model of Parkinson’s disease,” International Journal of Neuropsychopharmacology, vol. 23, no. 11, pp. 762–773, 2020. View at: Publisher Site | Google Scholar
  114. S.-F. Wang, L.-F. Liu, M.-Y. Wu et al., “Baicalein prevents 6-OHDA/ascorbic acid-induced calcium-dependent dopaminergic neuronal cell death,” Scientific Reports, vol. 7, no. 1, p. 8398, 2017. View at: Publisher Site | Google Scholar
  115. X. Zhang, L. Du, W. Zhang, Y. Yang, Q. Zhou, and G. Du, “Therapeutic effects of baicalein on rotenone-induced Parkinson’s disease through protecting mitochondrial function and biogenesis,” Scientific Reports, vol. 7, no. 1, p. 9968, 2017. View at: Publisher Site | Google Scholar
  116. S. N. Rai, V. K. Chaturvedi, P. Singh, B. K. Singh, and M. P. Singh, “Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective,” 3 Biotechnology, vol. 10, no. 12, p. 522, 2020. View at: Publisher Site | Google Scholar
  117. S. N. Rai, D. Mishra, P. Singh, E. Vamanu, and M. P. Singh, “Therapeutic applications of mushrooms and their biomolecules along with a glimpse of in silico approach in neurodegenerative diseases,” Biomedicine & Pharmacotherapy, vol. 137, p. 111377, 2021. View at: Publisher Site | Google Scholar

Copyright © 2021 Sicong Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views431
Downloads473
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.